<<For 30 years, Ora has been at the forefront of ophthalmic clinical research, building an unparalleled track record of success that includes full turnkey clinical services for 32 product approvals within the category. In fact, we have been directly involved in the development of over one-third of the world’s currently marketed ophthalmic pharmaceutical products.
Ora stands apart from all other research groups in that we have conducted over 1,200 clinical trials and consulting projects within the ophthalmology category. This deep knowledge and expertise has made Ora the preferred ophthalmic drug development partner for many of the top ophthalmic pharmaceutical companies in the world. Our unwavering mission is to apply our core scientific knowledge, regulatory expertise, and clinical excellence to give every drug its best chance to succeed.
Ora functions as a virtual R&D unit that has helped countless pharmaceutical companies develop new ophthalmic products from molecule to marketplace. Over the past three decades, we have provided turnkey operations for ophthalmic start-ups, mid-sized companies, publicly traded companies, and large multinationals.
Our reputation has been built upon a solid foundation of scientific rigor and research excellence. Since our founding, we have developed a series of proprietary clinical models that have consistently generated accurate and reliable data to support regulatory approvals, both in the US and around the world. We design, execute, and innovate the most efficient ophthalmic clinical development programs in the industry. We dedicate considerable resources towards internal research and development to advance ophthalmic clinical research design, including model innovation and evolution, endpoint development and evaluation, and clinical trial processes and management strategies.>>